Gland Pharma · NSE: GLAND · BSE: 543245
Q4 FY21 results · Jan–Mar 2021
Gland Pharma reported revenue from operations of ₹887.75 crore and net profit of ₹260.41 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 887.75 | — | — | — | — |
| Other income | 47.21 | — | — | — | — |
| Total income | 934.96 | — | — | — | — |
| Profit before tax | 348.94 | — | — | — | — |
| Net profit for the period | 260.41 | — | — | — | — |
| EPS, basic (₹) | 15.93 | — | — | — | — |
| Net margin (%) | 29.3 | — | — |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 887.75 | — | — | 859.42 | +3.3% |
| Other income | 47.21 | — | — | 35.13 | +34.4% |
| Total income | 934.96 | — | — | 894.55 | +4.5% |
| Profit before tax | 348.99 | — | — | 273.24 | +27.7% |
| Net profit for the period | 260.45 | — | — | 204.11 | +27.6% |
| EPS, basic (₹) | 15.93 | — | — | 12.83 | +24.2% |
| Net margin (%) | 29.3 | — | 23.7 |
Consolidated
- Filed with BSE
- 18 May 2021, 09:58 IST
- Board meeting
- 17 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2021, 09:58 IST
- Board meeting
- 17 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE